This document discusses the use of high-sensitivity C-reactive protein (hsCRP) as a biomarker for predicting cardiovascular disease risk. It notes that traditional risk factors have low sensitivity and specificity. HsCRP is emerging as a stronger predictor of risk than LDL and can help reclassify some patients as higher risk. Larger studies like the JUPITER trial are investigating using hsCRP levels to determine who may benefit from statin therapy independent of LDL levels. While hsCRP shows promise, more research is still needed to understand genetic and other factors that may influence hsCRP levels and risk predictions.